Learn more about Neovii world
Neovii and Fosun Pharma Enter into an Exclusive Agreement for Development and Commercialization for Grafalon in China (September 7, 2022, Rapperswil, Switzerland and Shanghai, China) Neovii Pharmaceuticals AG (“Neovii”), a Swiss based global specialty-care biopharmaceutical company, and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd (“Fosun Pharma Industry”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., […]
Rapperswil (Switzerland)/Gräfelfing (Germany), October 26, 2021: Dr. Christian Loss (57), former managing director of Neovii Biotech GmbH, Gräfelfing, is moving to the Swiss headquarters of Neovii Pharmaceuticals AG in Rapperswil as chief executive officer (CEO). As the new CEO in Germany, he will be succeeded by the former Neovii Head of Production, Sebastian Hofmann (40). […]
The epitope-based vaccine will target the most vulnerable part of the viral spike protein. Rapperswil, Switzerland and Tel Aviv, Israel, 12th May 2020 – Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially […]